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Anxiety, Depression, and Adverse Clinical Outcomes in Patients With
Atrial Fibrillation Starting Warfarin: Cardiovascular Research Network
WAVE Study
Christine Baumgartner, MD; Dongjie Fan, MSPH; Margaret C. Fang, MD, MPH; Daniel E. Singer, MD; Daniel M. Witt, PharmD;
John R. Schmelzer, PhD; Marc S. Williams, MD; Jerry H. Gurwitz, MD; Sue Hee Sung, MPH; Alan S. Go, MD
Background-—Anxiety and depression are associated with worse outcomes in several cardiovascular conditions, but it is unclear
whether they affect outcomes in atrial fibrillation (AF). In a large diverse population of adults with AF, we evaluated the association
of diagnosed anxiety and/or depression with stroke and bleeding outcomes.
Methods and Results-—The Cardiovascular Research Network WAVE (Community-Based Control and Persistence of Warfarin
Therapy and Associated Rates and Predictors of Adverse Clinical Events in Atrial Fibrillation and Venous Thromboembolism) Study
included adults with AF newly starting warfarin between 2004 and 2007 within 5 health delivery systems in the United States.
Diagnosed anxiety and depression and other patient characteristics were identified from electronic health records. We identified
stroke and bleeding outcomes from hospitalization databases using validated International Classification of Diseases, Ninth Revision
(ICD-9), codes. We used multivariable Cox regression to assess the relation between anxiety and/or depression with outcomes
after adjustment for stroke and bleeding risk factors. In 25 570 adults with AF initiating warfarin, 490 had an ischemic stroke or
intracranial hemorrhage (1.52 events per 100 person-years). In multivariable analyses, diagnosed anxiety was associated with a
higher adjusted rate of combined ischemic stroke and intracranial hemorrhage (hazard ratio, 1.52; 95% confidence interval, 1.01–
2.28). Results were not materially changed after additional adjustment for patient-level percentage of time in therapeutic
anticoagulation range on warfarin (hazard ratio, 1.56; 95% confidence interval, 1.03–2.36). In contrast, neither isolated depression
nor combined depression and anxiety were significantly associated with outcomes.
Conclusions-—Diagnosed anxiety was independently associated with increased risk of combined ischemic stroke and intracranial
hemorrhage in adults with AF initiating warfarin that was not explained by differences in risk factors or achieved anticoagulation
quality. ( J Am Heart Assoc. 2018;7:e007814. DOI: 10.1161/JAHA.117.007814.)
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A nxiety and depression are common disorders in theUnited States, with a lifetime risk of 29% and 17%,
respectively.1 Affected individuals are at increased risk of
cardiovascular events and death.2–4 Atrial fibrillation (AF) is
the most common clinically significant cardiac arrhythmia in
adults, with an estimated lifetime risk of 37% after age
55 years,5 and contributes to significant excess morbidity and
mortality.6,7 Both anxiety and depression frequently coexist
with AF,8 but it is unclear whether anxiety and depression are
associated with differences in outcomes in people with AF.
A recent study has shown that patients with AF with
mental health disorders, such as anxiety or psychosis, who
are eligible for warfarin therapy are less likely to receive
treatment than patients without mental health disorders. This
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is possibly because of providers’ concerns about noncompli-
ance with a complicated medication regimen,9 suggesting an
uncertainty among healthcare providers about the risk-benefit
profile of warfarin among these patients. Evidence on treat-
ment outcomes related to warfarin in patients with mental
health disorders is sparse, and understanding the impact of
anxiety and depression on clinical outcomes in patients on
anticoagulation treatment is crucial to improve their manage-
ment by identifying those who might benefit from more
intensive monitoring or alternative anticoagulation strategies.
Therefore, we examined the association between diag-
nosed anxiety or depression with adverse clinical outcomes in
adults initiating warfarin therapy for AF.
Methods
Study Design and Setting
The WAVE (Community-Based Control and Persistence of
Warfarin Therapy and Associated Rates and Predictors of
Adverse Clinical Events in Atrial Fibrillation and Venous
Thromboembolism) project in the Cardiovascular Research
Network10 was a retrospective cohort study of adults with AF
who were enrolled in 1 of 5 large integrated healthcare
systems in the United States: Kaiser Permanente Northern
California, which served >3.2 million members in Northern
California; Kaiser Permanente Colorado, which served
>460 000 members in the metropolitan area of Denver, CO;
Geisinger, which served >1 million patients (of whom
450 000 members were covered by the Geisinger Health
Plan) in central and northeast Pennsylvania; Marshfield Clinic,
which served >550 000 members in central and northwest
Wisconsin; and Harvard Pilgrim, which served >1 million
members in New England during the study period. These
healthcare systems represent demographically and socioeco-
nomically diverse community-based populations in the speci-
fic geographic areas.11 Research divisions from these
healthcare delivery systems each created site-specific virtual
data warehouses containing individual patient information
from electronic medical records and administrative databases
to promote interinstitutional research.10 The virtual data
warehouse was the primary data source for identification of
patients and characterization of covariates in our study, and
mortality data were obtained from State Death files and the
National Death Index.
The study was approved by the institutional review boards
of the participating organizations. Because of the nature of
the study, a waiver of informed consent was obtained.
If requested, a complete, cleaned, deidentified copy of the
data set can be made available through the Cardiovascular
Research Network. For information on the data elements,
format, and security, see CVRN.org. The Cardiovascular
Research Network has a standard approach for data sharing
that includes review of requests by the project Steering
Committee based on the following: (1) high scientific merit;
(2) consistency with the overall goals and objectives of the
parent study; (3) provision of adequate resources to effectively
complete the project, including sufficient budget to cover costs
of personnel and data acquisition; (4) the requisite expertise to
meet the objectives of the project; and (5) inclusion of the
parent study team member(s) as part of the investigative team.
Cohort Assembly
Eligible adults had a diagnosis of AF or atrial flutter and were
newly initiating warfarin therapy between January 1, 2004,
and December 31, 2007. AF diagnoses were based on a
primary hospital discharge diagnosis of AF (International
Classification of Diseases, Ninth Revision [ICD-9] code 427.31
or 427.32) or ≥2 outpatient diagnoses of AF found in health
plan databases. Information on warfarin prescription was
obtained from dispensing data found in health plan pharmacy
databases. The index date of warfarin therapy was defined as
new warfarin dispensing without prior evidence of receiving
warfarin within 3 years before the index dispensing date. Time
on warfarin was based on the number of days supplied per
prescription and intervening international normalized ratio
(INR) tests using a previously validated algorithm.12 We
included adults who were ≥21 years at their index warfarin
prescription date, had at least 1 outpatient INR measurement
after the index date, and had ≥12 months of continuous
health plan membership and pharmacy drug benefit before
Clinical Perspective
What Is New?
• The impact of anxiety and depression diagnoses on adverse
outcomes in patients with atrial fibrillation anticoagulated
with warfarin is unclear.
• In a large cohort of adults with atrial fibrillation newly
starting warfarin, diagnosed anxiety was associated with an
increased risk of combined ischemic stroke and intracranial
hemorrhage during follow-up, whereas depression or com-
bined depression and anxiety was not.
• This risk increase was not mediated by anticoagulation
quality.
What Are the Clinical Implications?
• Diagnosed anxiety might be useful for further stratification
of stroke and bleeding risk in patients with atrial fibrillation
who newly start warfarin.
• Future studies should investigate underlying mechanisms
and assess whether different treatment approaches might
relate to improved outcomes in these patients.
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study entry to ensure minimum necessary information on
patient characteristics. Individuals with any warfarin exposure
in the 3 years before study entry were excluded.
Primary Predictors: Diagnosed Anxiety and/or
Depression
We considered anxiety and/or depression diagnoses that were
present at entry. Study participants were considered to have
prevalent anxiety or depression at baseline if they had ≥2
outpatient diagnoses within 12 months of each other or 1
inpatient primary diagnosis based on ICD-9 codes found in
health plan databases. A diagnosis of anxiety was defined as the
presence of any of the following ICD-9 codes: 300.0x, 300.2x,
300.3, 309.20, 309.21, 309.24, and 309.81. A diagnosis of
depression was defined as any of the following ICD-9 codes:
296.2x, 296.3x, 296.82, 298.0, 300.4, 301.12, 309.0, 309.1,
309.28, and 311, as has been used in a previous study.13
Outcomes
Follow-up started at the first warfarin dispensing date and
ended on the date of an outcome event, withdrawal from the
health plan, termination of warfarin use, death not attributable
to an outcome event, or end of the study on December 31,
2007, whichever came first. Clinical events potentially related
to AF or warfarin treatment were chosen as outcomes. The
primary outcome was the rate of combined ischemic stroke
and/or intracranial hemorrhage (ICH), the 2 most influential
factors driving net clinical benefit of anticoagulation for AF.14
We also examined as a secondary outcome hospitalizations
for extracranial hemorrhage. Clinical outcomes were identified
by searching computerized hospitalization and billing data-
bases for relevant ICD-9 codes (Data S1), and only the first
event of each type was recorded. The diagnosis of ischemic
stroke (ICD-9 code 433.01, 433.11, 433.21, 433.31, 433.81,
433.91, 434.01, 434.11, 434.91, or 436) was based on a
relevant code in the primary hospital discharge position and
ICH on a primary or secondary hospital discharge
diagnosis.10,15 Hospitalizations for extracranial hemorrhage
were identified by appropriate ICD-9 codes in the primary
position. Because all patients in this cohort were enrolled in
healthcare delivery systems, we were able to identify outcomes
even when patients presented to institutions outside of the
particular healthcare delivery network, because care provided
outside of owned facilities is systematically tracked.
Covariates
We used the virtual data warehouse to obtain information on
age, sex, race, relevant medical history, comorbid conditions,
and other cardiovascular risk factors at baseline using
previously validated approaches based on ICD-9 diagnosis
and procedure codes, Current Procedure Terminology proce-
dure codes, laboratory records, and pharmacy records.15,16
Anticoagulation quality was defined as the percentage of
time in a therapeutic INR range of 2.0 to 3.0. It was calculated
as the total time that the patient had an INR between 2.0 and
3.0, estimated using a modified linear interpolation between
measured INR points, divided by the total time the patient was
on warfarin.17 Baseline renal function using serum creatinine
concentration values was obtained from health system
laboratory databases and estimated by the glomerular
filtration rate (mL/min per 1.73 m2) using the Chronic Kidney
Disease Epidemiology Collaboration equation.18
We searched health plan pharmacy databases for dispensed
prescriptions for anxiolyticmedications (buspirone, alprazolam,
chlordiazepoxide, clonazepam, clorazepate, diazepam, loraze-
pam, estazolam, halazepam, oxazepam, prazepam, and quaze-
pam) and antidepressant medications available during the
study period (amitriptyline, amoxapine, bupropion, citalopram,
clomipramine, desipramine, doxepin, duloxetine, escitalopram,
fluoxetine, fluvoxamine, imipramine, maprotiline, mirtazapine,
nefazodone, nortriptyline, paroxetine, phenelzine, protriptyline,
selegiline, sertraline, tranylcypromine, trazodone, trimipramine,
and venlafaxine). We also searched for cardiovascular medica-
tions, including angiotensin-converting enzyme inhibitors,
aldosterone receptor antagonists, b blockers, digoxin, diuret-
ics, nitrates, and statins.
Statistical Analysis
All analyses were performed using SAS statistical software,
version 9.3 (Cary, NC). Group differences for baseline charac-
teristics in patients stratified by anxiety and/or depression
diagnoses were compared using ANOVA test for continuous
variables and the v2 test for categorical variables. Multivariable
extended Cox regression models using time-updated covari-
ates were used to assess the relations between diagnosed
anxiety and/or depression and incident adverse outcomes,
adjusting for patient demographic factors, baseline medical
conditions, renal function, and hemoglobin. We then further
adjusted the analyses for the percentage of time in therapeutic
INR range over each patient’s follow-up period, and then
performed an analysis adjusting for baseline anxiolytic and
antidepressant as well as cardiovascular medication use. To
assess whether results applied to the subgroup of patients
without prior ischemic stroke, we added a sensitivity analysis
restricted to patients without a history of stroke at baseline.
Results
We identified 25 570 eligible adults with diagnosed AF
initiating a new course of warfarin therapy (Figure). A total
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of 897 participants (3.5%) had a diagnosis of anxiety only, 2322
(9.1%) had a diagnosis of depression only, and 904 (3.5%) had
combined anxiety and depression (Table 1). Mean age was
72.3 years, and 43.5% were women in the overall cohort.
Patients with a combined diagnosis of depression and anxiety
were more likely to have a history of myocardial infarction,
unstable angina, or percutaneous coronary intervention,
whereas those without anxiety or depression were more likely
to have diagnosed hypertension, but less likely to be affected
by dementia or chronic lung or liver disease compared with the
other subgroups. The percentage of time in therapeutic INR
range differed among the 4 groups. It was 57% in patients
without depression or anxiety and those with anxiety only,
whereas it was 52% and 53% in patients with depression and
those with combined depression and anxiety, respectively.
P value < 0.001; results not shown.
Diagnosed Anxiety and/or Depression and
Combined Ischemic Stroke and ICH
The median follow-up was 339 days (interquartile range, 131–
708 days), with a maximum follow-up of 1460 days. In the
overall cohort, 490 (1.9%) experienced an ischemic stroke or
ICH event, for a rate of 1.52 events per 100 person-years
(Table 2). In multivariable adjusted analyses, diagnosed
anxiety was associated with a significantly higher adjusted
rate of combined ischemic stroke and ICH (hazard ratio, 1.52;
95% confidence interval, 1.01–2.28), whereas depression was
not (Table 3). Additional adjustment for patient-level time in
therapeutic INR range did not materially affect the multivari-
able association between diagnosed anxiety and the risk of
combined ischemic stroke and ICH (hazard ratio, 1.56; 95%
confidence interval, 1.03–2.36). Further adjustment for the
receipt of anxiolytic and antidepressant drugs or cardiovas-
cular drugs did not lead to a meaningful change in the results
(Table 3). In a sensitivity analysis with exclusion of patients
with a history of ischemic stroke at baseline, a statistically
significant association between diagnosed anxiety and com-
bined ischemic stroke and ICH remained (adjusted hazard
ratio, 1.56; 95% confidence interval, 1.03–2.36; Table S1).
Association Between Diagnosed Anxiety and/or
Depression and Secondary Outcomes
Crude event rates of individual clinical outcomes are
presented in Table 2. Diagnosed anxiety was associated with
higher adjusted hazard ratios for ischemic stroke, ICH, and
extracranial hemorrhage, but the associations were not
statistically significant (Table 4). Neither diagnosed depres-
sion alone nor the combination of anxiety and depression was
significantly associated with ischemic stroke, ICH, or hospi-
talization for extracranial hemorrhage (Table 4).
Discussion
In a large, multicenter, community-based cohort of adults
newly treated with warfarin for AF, we found that having
diagnosed anxiety was associated with an increased risk for
Figure. Selection of the final study population. INR indicates international normalized ratio.
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worse outcomes independent of known risk factors and the
quality of anticoagulation therapy. In contrast, diagnosed
depression was not associated with an increased risk of
adverse events in this population.
Other studies have noted that certain mental health
conditions are associated with adverse cardiovascular out-
comes,4,19,20 but this has only been evaluated in patients with
AF in a limited number of studies. A recent retrospective
Table 1. Characteristics of Study Participants at Baseline
Characteristic
No Anxiety or Depression
(n=21 447)
Diagnosed Anxiety
Only (n=897)
Diagnosed
Depression
Only (n=2322)
Diagnosed Anxiety
and Depression (n=904) P Value
Age, mean (SD), y 72.3 (11.2) 72.2 (11.5) 72.3 (10.8) 71.3 (11.5) 0.051
Female sex, n (%) 8711 (40.6) 554 (61.8) 1296 (55.8) 561 (62.1) <0.001
Race, n (%) 0.005
White 16 946 (79.0) 727 (81.1) 1930 (83.1) 754 (83.4)
Black 988 (4.6) 23 (2.6) 90 (3.9) 28 (3.1)
Asian/Pacific Islander 1556 (7.2) 62 (6.9) 86 (3.7) 31 (3.4)
Other 441 (2.1) 30 (5.2) 70 (3.0) 35 (3.9)
Unknown 1516 (7.1) 55 (6.1) 146 (6.3) 56 (6.2)
Medical history, n (%)
Acute myocardial infarction 1141 (5.3) 47 (5.2) 163 (7.0) 68 (7.5) 0.008
Unstable angina 771 (3.6) 42 (4.7) 104 (4.5) 49 (5.4) 0.008
Coronary artery bypass surgery 766 (3.6) 20 (2.2) 89 (3.8) 28 (3.1) 0.47
Percutaneous coronary intervention 808 (3.8) 29 (3.2) 100 (4.3) 46 (5.1) 0.048
Ischemic stroke 1247 (5.8) 50 (5.6) 171 (7.4) 65 (7.2) 0.12
Transient ischemic attack 798 (3.7) 37 (4.1) 114 (4.9) 44 (4.9) 0.12
Other arterial thromboembolic event 188 (0.9) 7 (0.8) 30 (1.3) 10 (1.1) 0.55
Intracranial hemorrhage 123 (0.6) 4 (0.5) 24 (1.0) 7 (0.8) 0.54
Gastrointestinal hemorrhage 467 (2.2) 28 (3.1) 77 (3.3) 30 (3.3) 0.052
Other hospitalized bleed 138 (0.6) 8 (0.9) 17 (0.7) 9 (1.0) 0.23
Systemic cancer 3209 (15.0) 136 (15.2) 397 (17.1) 132 (14.6) 0.64
Chronic heart failure 4896 (22.8) 187 (20.9) 632 (27.2) 227 (25.1) 0.17
Diabetes mellitus 5408 (25.2) 195 (21.7) 741 (31.9) 230 (25.4) 0.85
Diagnosed hypertension 8050 (37.5) 302 (33.7) 757 (32.6) 282 (31.2) <0.001
Diagnosed dementia 651 (3.0) 42 (4.7) 234 (10.1) 97 (10.7) <0.001
Chronic lung disease 3877 (18.1) 187 (20.9) 533 (23.0) 198 (21.9) 0.014
Chronic liver disease 428 (2.0) 24 (2.7) 76 (3.3) 32 (3.5) 0.005
Dyslipidemia 7977 (37.2) 324 (36.1) 876 (37.7) 332 (36.7) 0.77
Mechanical fall 349 (1.6) 16 (1.8) 86 (3.7) 37 (4.1) <0.001
Baseline eGFR (mL/min per 1.73 m2), n (%) <0.001
≥60 13 104 (61.1) 594 (66.2) 1419 (61.1) 602 (66.6)
30–59 6766 (31.5) 260 (29.0) 720 (31.0) 259 (28.7)
<30 or dialysis 881 (4.1) 25 (2.8) 132 (5.7) 31 (3.4)
eGFR missing 696 (3.3) 18 (2.0) 51 (2.2) 12 (1.3)
Medication history, n (%)
Antidepressant medication 2321 (10.8) 245 (27.3) 1442 (62.1) 606 (67.0) <0.001
Antianxiety medication 1550 (7.2) 348 (38.8) 361 (15.6) 388 (42.9) <0.001
eGFR indicates estimated glomerular filtration rate.
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cohort study among >100 000 patients on warfarin (≥65 000
with AF) from the Veterans Health Administration found that
the risk of hemorrhage was slightly higher in those with
mental health disorders (such as depression) compared with
those without mental health disorders.21 However, this
previous study included only patients who were taking
warfarin for at least 6 months and likely represented a
selected subset of patients who tolerated anticoagulation
better.22 Another study using data from a Medicaid admin-
istrative claims database found an association between any
psychiatric illness and an increased risk of thromboembolic
and hemorrhagic events among patients with AF on warfarin,
but did not specifically examine risk according to type of
underlying condition.23
The mechanism behind the association of anxiety and
adverse outcomes is not clear. In our study, we examined
whether the increased risk of adverse events in patients with
diagnosed anxiety may have been related to anticoagulation
control, which is potentially modifiable. Anticoagulation
quality depends on multiple factors, including age, sex, the
targeted INR,24 the frequency of INR monitoring,25 medication
adherence,26 diet, comorbidities,24 and drug-drug
interactions27; some of these factors may be negatively
affected by mental health disorders.28–30 However, adjust-
ment for patient-level time in therapeutic INR range did not
materially affect the strength of association for anxiety and
outcomes. Information on certain behavioral factors (eg,
smoking and physical inactivity)31 that may potentially
confound the relationship between anxiety and outcomes
was not consistently available and, thus, could not be
analyzed. An intriguing avenue of further investigation may
be how anxiety-related stress can lead to alterations in
hemostasis.32,33 Autonomic arousal in the context of anxiety
may result in physiologic changes, such as an increase in
blood pressure,34 that are associated with the risk of both
ischemic stroke and intracranial bleeding events.
We did not find a significant association between depres-
sion and adverse events in AF. Depression has been
extensively studied as an independent risk factor for health
outcomes, including cardiovascular disease and death,2,3,35
Table 2. Crude Outcome Event Rates in Adults on Warfarin for AF
Mental Health
Condition People, No.
Combined Ischemic Stroke and
ICH Ischemic Stroke ICH
Hospitalization for Extracranial
Hemorrhage
Events, No.
Event Rate per
100 Person-Years Events, No.
Event Rate per
100 Person-Years
Events,
No.
Event Rate per
100 Person-Years Events, No.
Event Rate per
100 Person-Years
Overall 25 570 490 1.52 307 0.95 205 0.63 867 2.69
No anxiety, no
depression
21 447 395 1.43 247 0.89 168 0.60 724 2.63
Anxiety only 897 24 2.32 16 1.54 10 0.96 32 3.10
Depression only 2322 54 2.06 30 1.14 24 0.91 87 3.31
Both anxiety and
depression
904 17 1.74 14 1.43 3 0.30 24 2.44
AF indicates atrial fibrillation; and ICH, intracranial hemorrhage.
Table 3. Serial Multivariable Analyses for the Association Between Anxiety and/or Depression and the Risk of Combined Ischemic
Stroke and ICH in Adults With AF Initiating Warfarin Therapy
Mental Health Condition Adjusted HR (95% CI)*
HR Additionally Adjusted
for TTR (95% CI)
HR Additionally Adjusted
for Use of Anxiolytic and
Antidepressant Drugs (95% CI)†
HR Additionally Adjusted
for Use of Cardiac Drugs (95% CI)‡
No anxiety, no depression Reference Reference Reference Reference
Anxiety only 1.52 (1.01–2.28) 1.56 (1.03–2.36) 1.57 (1.01–2.43) 1.54 (0.99–2.38)
Depression only 1.20 (0.89–1.61) 1.14 (0.85–1.53) 1.07 (0.78–1.48) 1.08 (0.78–1.49)
Both anxiety and depression 0.93 (0.63–1.70) 0.98 (0.60–1.61) 0.95 (0.58–1.59) 0.96 (0.57–1.61)
AF indicates atrial fibrillation; CI, confidence interval; HR, hazard ratio; ICH, intracranial hemorrhage; and TTR, percentage of time in therapeutic international normalized ratio range.
*Adjusted by patient sex, baseline age, race, renal function, hemoglobin level, history of cancer, ischemic and hemorrhagic stroke, acute myocardial infarction, unstable angina, coronary
artery bypass surgery, percutaneous coronary intervention, transient ischemic attack, intracranial hemorrhage, gastrointestinal bleeding, other major bleeding, other thromboembolic
event, chronic heart failure, dementia, lung disease, liver disease, dyslipidemia, hypertension, mechanical fall, and diabetes mellitus.
†Adding baseline use of anxiolytic and antidepressant medications. Baseline definition is for drug prescribed 120 days before the index or at index date.
‡Adding baseline cardiac drug use, including angiotensin-converting enzyme inhibitors, aldosterone receptor antagonists, b blockers, digoxin, diuretics, nitrates, and statins. Baseline
definition is for drug prescribed 120 days before the index until 90 days after index.
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not only among the general population, but also in patients
receiving anticoagulation.36,37 Our study relied on ICD-9
codes to define anxiety and depression, and it is possible that
a diagnosis of anxiety may be less sensitive for underlying
anxiety disorders compared with depression diagnoses.
Generalized anxiety disorder may be more underrecognized
than major depression.38 A comparatively decreased sensi-
tivity in anxiety diagnoses might lead to a selection of anxiety
patients with higher disease severity, which could explain the
increased risk of adverse outcomes in this population
compared with patients with depression diagnoses or the
combination of depression and anxiety.
A strength of our study is that we were able to include a
large number of patients with diagnosed anxiety and depres-
sion from a geographically and ethnically diverse population of
anticoagulated patients with AF. By including patients newly
treated with warfarin, our study reflects outcomes from the
start of treatment in real-life clinical practice, where the choice
of whether to anticoagulate a patient must be made without
proven tolerance or patient adherence. We ascertained longi-
tudinal warfarin exposure and assessed patient-level time in
therapeutic INR range, which allowed us to examine the
potential impact of anticoagulation control on our results.
Our study also had limitations. Although there was a
consistent pattern of an increased rate of stroke and bleeding
outcomes in patients with diagnosed anxiety compared with
those without anxiety or depression, our results did not reach
statistical significance for the individual secondary outcomes
(ischemic stroke, ICH, and hospitalization for extracranial
hemorrhage), possibly because of insufficient power. As noted
previously, anxiety disorders and depression are often under-
diagnosed,39 which would likely lead to nondifferential
misclassification that would bias our results towards the null.
We also cannot exclude residual confounding by variables that
are difficult to obtain from electronic health records, such as
genetic factors, socioeconomic status and social net-
work,40,41 or stress,32 and we were not able to assess the
role of physical inactivity or smoking in the association
between anxiety or depression and adverse outcomes.31 Our
study relied on anxiety and depression diagnosed in the
medical record, which likely identified more severe cases.
Finally, our results may not be completely generalizable to all
populations and practice settings.
Given a consistent trend towards a higher risk of adverse
events in patients with diagnosed anxiety, future research
should investigate whether different treatment approaches
might be associated with more favorable risk-benefit profile in
these patients. The increased risk of adverse events did not
seem to be mediated by poor INR control, so more intensive
INR monitoring might, therefore, not be sufficient to prevent
adverse events in these patients. Whether anticoagulation
with direct oral anticoagulants reduces the risk of adverse
events in patients with anxiety remains to be examined.
Additional studies are needed to confirm our findings and
further explore underlying mechanisms and optimal manage-
ment strategies.
In conclusion, diagnosed anxiety, but not depression, was
linked to a higher rate of combined ischemic stroke and ICH in
adults with AF initiating anticoagulation. This information may
be helpful in further risk stratifying patients with AF.
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SUPPLEMENTAL MATERIAL 
 
 Data S1. 
 
Supplemental Methods. International Classification of Diseases, 9th Edition (ICD-9) Codes 
Used for the Definition of Outcomes of Interest 
 
Ischemic Stroke:  
Principal hospital discharge diagnosis of following ICD-9 codes: 
433.01, 433.11, 433.21, 433.31, 433.81, 433.91, 434.01, 434.11, 434.91, 436. 
Intracranial Hemorrhage: 
Primary or secondary hospital discharge diagnosis of following ICD-9 codes:  
430, 431, 432, 432.0, 432.1, 432.9, 852, 852.0, 852.00, 852.01, 852.02, 852.03, 852.04, 
852.05, 852.06, 852.09, 852.1, 852.10, 852.11, 852.12, 852.13, 852.14, 852.15, 852.16, 
852.19, 852.2, 852.20, 852.21, 852.22, 852.23, 852.24, 852.25, 852.26, 852.29, 852.3, 
852.30, 852.31, 852.31, 852.33, 852.34, 852.35, 852.36, 852.39, 852.4, 852.40, 852.41, 
852.42, 852.43, 852.44, 852.45, 852.46, 852.49, 852.5, 852.50, 852.51, 852.52, 852.53, 
852.54, 852.55, 852.56, 852.59, 853, 853.0, 853.00, 853.01, 853.02, 853.03, 853.04, 853.05, 
853.06, 853.09, 853.1, 853.10, 853.11, 853.12, 853.13, 853.14, 853.15, 853.16, 853.19. 
Hospitalization for Extracranial Hemorrhage  
ICD-9 codes for gastrointestinal bleeding or other bleeding in the primary position: 
455.2, 455.5, 455.8, 456.0, 456.20, 530.7, 530.82, 531.00, 531.01, 531.20, 531.21, 531.40, 
531.41, 531.60, 531.61, 532.00, 532.01, 532.20, 532.21, 532.40, 532.41, 532.60, 532.61, 
533.00, 533.01, 533.20, 533.21, 533.40, 533.41, 533.60, 533.61, 534.00, 534.01, 534.20, 
534.21, 534.40, 534.41, 534.60, 534.61, 535.01, 535.11, 535.21, 535.31, 535.41, 535.51, 
 535.61, 537.83, 562.02, 562.03, 562.12, 562.13, 568.81, 569.3, 569.85, 578.0, 578.1, 578.9, 
423.0, 599.7, 719.11, 784.7, 784.8, 786.3, 287.8, 287.9, 627.0 , 627.1 , 626.2, 998.11, 459.0.
 Table S1.Main and Sensitivity Analysis for the Association between Anxiety and/or 
Depression and the Risk of Combined Ischemic Stroke and Intracranial Hemorrhage in 
Adults with Atrial Fibrillation Initiating Warfarin Therapy 
Mental Health Condition Adjusted HR (95% CI)* 
Adjusted HR (95% CI)* Restricted 
to Patients Without a History of 
Ischemic Stroke at Baseline 
No anxiety, no depression Reference Reference 
Anxiety only 1.52 (1.01 - 2.28) 1.56 (1.03 – 2.36) 
Depression only 1.20 (0.89 - 1.61) 1.16 (0.87 – 1.55) 
Both anxiety and depression 0.93 (0.63 - 1.70) 1.03 (0.63 – 1.68) 
 
Abbreviations: CI, confidence interval; HR, hazard ratio. 
*Adjusted by patient sex, baseline age, race, renal function, hemoglobin level, history of 
cancer, ischemic and hemorrhagic stroke, acute myocardial infarction, unstable angina, 
coronary artery bypass surgery, percutaneous coronary intervention, transient ischemic 
attack, intracranial hemorrhage, gastrointestinal bleeding, other major bleeding, other 
thromboembolic event, chronic heart failure, dementia, lung disease, liver disease, 
dyslipidemia, hypertension, mechanical fall, diabetes mellitus. 
